Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.36 |
| ▸ | TUBB | P07437 | 4/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490531 | 1.00 | CYP3A4 (0.54) | CYP3A4TNFRSF1ATUBB4ATUBBTUBA3C | |
| SCHEMBL6832451 | 0.90 | CYP3A4 (0.52) | CYP3A4TNFRSF1ATUBB4ATUBBTUBA3C | |
| SCHEMBL2489645 | 0.85 | CYP3A4 (0.73) | CYP3A4TNFRSF1AERBB2SNCAFYN | |
| SCHEMBL2489644 | 0.85 | CYP3A4 (0.73) | CYP3A4TNFRSF1AERBB2SNCAFYN | |
| SCHEMBL1764331 | 0.83 | CYP3A4 (0.74) | CYP3A4TNFRSF1ATUBB4ATUBBTUBA3C | |
| SCHEMBL1764330 | 0.83 | CYP3A4 (0.74) | CYP3A4TNFRSF1ATUBB4ATUBBTUBA3C | |
| SCHEMBL6832515 | 0.82 | CYP3A4 (0.43) | CYP3A4PTGS2 | |
| SCHEMBL1764839 | 0.79 | CYP3A4 (0.65) | CYP3A4SNCAFYN | |
| SCHEMBL6832471 | 0.79 | PTGS2 (0.38) | CYP3A4ERBB2EGFRADORA2AADORA1 | |
| SCHEMBL1542800 | 0.78 | CYP3A4 (0.70) | CYP3A4TNFRSF1ANFE2L2ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885TNFRSF1A 3504/4885TUBB4A 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.